SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ggamer who wrote (342)10/5/2007 6:36:55 PM
From: Keith FeralRead Replies (1) of 418
 
I think the mgmt bent over backwards to stress that they would be talking to their marketing partners about the clinical relevance. They have to show the partners the Cofactor group had some underlying cancer problems that caused the different results. And they have to discuss why the folate effect did not happen. They mentioned the method of administration negated the folate effect.

I listened to the whole call several times and took notes of all of Merritt's comments. They are worth going back to hear. I'm not going to wait for an answer from the company, which is why I'm going through all the clinical work.

It wasn't the infusional Cofactor and 5FU that was the problem, it was the 600 mg of 5FU that overloaded the folate. Normally, Cofactor is dosed with 50 mg per 450 mg of 5FU. The problem with the infusion was an extra 600 mg of 5FU added to the regimen in the 22 hour continous infusion. This must have prevented the supply of folate from increasing the RBC folate levels.

I hope for all our sakes the company can convince the marketing partners so they can get some money for the phase 3. I don't see 10 mg Avastin solutions interfering with Cofactor to express the folate effect. Plus, people are only getting dosed with Avastin every other week and they are getting bolus Cofactor or Leucovorin every week. Bottom line, I don't think they could have constructed the phase 3 any better. Maybe they could have done a 3rd arm to study 2 hour Cofactor infusion vs 2 hour Leucovorin for the same doses. However, I don't think there is any reason to suspect that the 2 hour infusion is the cause of the problem so much as the dilution of the Cofactor from the second infusion of 600 mg.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News